Disease Domain | Count |
---|---|
Neoplasms | 3 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Antibody drug conjugate (ADC) | 3 |
Top 5 Target | Count |
---|---|
CLDN6 x Tubulin(Claudin 6 x Tubulin) | 2 |
CLDN18.2 x Tubulin(Claudin 18.2 x Tubulin) | 1 |
Target |
Mechanism CLDN6 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CLDN6 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CLDN18.2 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date06 Feb 2014 |
Sponsor / Collaborator |
Start Date05 Nov 2010 |
Sponsor / Collaborator |
Start Date01 Sep 2010 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Anti-claudin 6 antibody-drug conjugate(Ganymed Pharmaceuticals) ( CLDN6 x Tubulin ) | Neoplasms More | Preclinical |
IMAB 027-vcMMAE ( CLDN6 x Tubulin ) | Neoplasms More | Preclinical |
IMAB362-vcMMAE ( CLDN18.2 x Tubulin ) | Stomach Cancer More | Preclinical |
IMAB-027 ( CLDN6 ) | Testicular Neoplasms More | Discontinued |
6PHU3 (BioNTech SE) ( CD3 x CLDN6 ) | Neoplasms More | Pending |